Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Rep. Mike Collins heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural prayer ...

Millions of us take vitamins, minerals, and other supplements daily to improve our health and well-being—but taking certain ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

“Most of my new patients come through word of mouth,” says Dr. Boling. Her advice: Look at neighborhood chat groups. Ask friends who their doctors are and why they like them. Have a friend who’s a ...

In an analysis of health data from 130million people, British researchers found medications which could potentially increase, ...

Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms ...

Many Canadians struggle with SAD, a real form of depression that can make navigating the winter months extremely difficult.

New recommendations on how to define obesity would reduce the emphasis on body mass index and take into account health ...